VY7523 for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Who Is on the Research Team?
Chief Medical Officer
Principal Investigator
Voyager Therapuetics, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals with early Alzheimer's Disease. Participants should have a diagnosis of Alzheimer's and be in the initial stages of the disease. They must have previously tolerated similar studies well, if applicable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple ascending intravenous doses of VY7523 or placebo, with dose escalation based on safety reviews
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants in Cohort 3 are monitored for long-term effects and efficacy of the high dose
What Are the Treatments Tested in This Trial?
Interventions
- VY7523
Find a Clinic Near You
Who Is Running the Clinical Trial?
Voyager Therapeutics
Lead Sponsor